Comparative Pharmacology
Head-to-head clinical analysis: AURLUMYN versus JYLAMVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AURLUMYN versus JYLAMVO.
AURLUMYN vs JYLAMVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
JYLAMVO (methotrexate) is a folate analog that inhibits dihydrofolate reductase (DHFR), thereby disrupting DNA synthesis and repair. It also inhibits purine and thymidylate synthesis, leading to immunosuppressive and antineoplastic effects.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Oral: 30 mg twice daily for adults with relapsed or refractory acute myeloid leukemia (AML) as a monotherapy.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 12-16 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Primarily renal elimination as unchanged drug (approximately 70-80%) with minor biliary/fecal excretion (20-30%).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent